Orforglipron Cuts A1C by 2.2% vs Semaglutide, Eyes Q2 2026 US Approval
Orforglipron 36 mg delivered a 2.2% A1C reduction versus 1.4% for oral semaglutide in the 52-week ACHIEVE-3 Phase 3 trial of 1,698 type 2 diabetes patients on metformin. Participants on Lilly’s drug lost an average 19.7 lbs (9.2%), a 73.6% greater reduction than semaglutide, with U.S. obesity approval targeted in Q2 2026.
1. ACHIEVE-3 Phase 3 Head-to-Head Trial
The 52-week ACHIEVE-3 trial enrolled 1,698 adults with type 2 diabetes inadequately controlled on metformin, directly comparing Lilly’s oral GLP-1 candidate orforglipron with Novo Nordisk’s oral semaglutide in primary and key secondary efficacy endpoints.
2. Superior A1C and Weight Loss Outcomes
Orforglipron 36 mg achieved a 2.2% reduction in A1C versus 1.4% for semaglutide 14 mg, and delivered an average 19.7 lbs (9.2%) weight loss, representing a 73.6% greater reduction compared to semaglutide.
3. Global Regulatory Submissions and U.S. Timeline
Lilly has submitted orforglipron for approval in over 40 countries, with a U.S. decision for obesity treatment expected in the second quarter of 2026 based on ACHIEVE-3 data.
4. Competitive and Market Implications
Orforglipron’s data positions Lilly to challenge Novo Nordisk’s oral semaglutide franchise, while shares dropped nearly 2% and were trading 5.2% below their 20-day and 8.4% below their 100-day moving averages during a broader market decline.